Endo Pharmaceuticals (ENDP) Target Rasied to $44 on Old OxyContin Win from FDA
Tweet Send to a Friend
Jefferies raised its price target on Buy-rated Endo Pharmaceuticals Holdings Inc (NASDAQ: ENDP) from $36 to $44 on news the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
